Kyle LaHucik

RT @AndrewE_Dunn: NEW: Google’s bet on AI in drug discovery just got a lot bigger. My latest with @ky_lahucik on Isomorphic's $600 million…

RT @jeanniereporter: What Drew said. Also, the CBER director is not subject to Senate confirmation, so the administration can hire anyone…

RT @ArmstrongDrew: This is going to be an absolutely huge deal in the biotech sector, where Marks was seen as somebody pushing for new ther…

RT @maxonwifi: another @endpts scoop: Lykos interim CEO Michael Mullette is planning to step down after new investors take over the psyched…

RT @ZacharyBrennan: HHS plans to cut 10,000 more staffers in major downsizing - https://t.co/IUZyzikA9s

Trump administration is slashing 24% of the staff at Department of Health and Human Services, which is led by recently confirmed secretary RFK Jr. https://t.co/LgSvPIY8Wv

New: Lyndra Therapeutics, a decade-old biotech attempting to make long-acting versions of major medicines, is folding operations, a source familiar with the situation told @endpts on Tuesday The biotech, a spinout of Bob Langer’s MIT lab, raised $380M+ https://t.co/R66naUinhs

RT @maxonwifi: "A person who was briefed on the meeting said Kennedy didn’t want to turn stem cell regulation into the 'Wild West.'" Grea…

this trip was worth it for many reasons, but mainly because @g0ingmad and I met the person who claims they coined the “where fun goes to die” characterization of University of Chicago (she works in biotech)

Kyle LaHucik @ky_lahucik

Prepared for Miami by staying out till 3:30 this morning back home in Chicago … but the sunshine is curing my exhaustion and allowing me to handle the gloomy biotech industry sentiment https://t.co/LDewpM5wcm

Prepared for Miami by staying out till 3:30 this morning back home in Chicago … but the sunshine is curing my exhaustion and allowing me to handle the gloomy biotech industry sentiment https://t.co/LDewpM5wcm

“They are the FDA’s premier drug analysis lab,” former FDA Acting Commissioner Janet Woodcock told @endpts by email. “Congress has been constantly on FDA to make sure imported drugs are of adequate quality, and the St. Louis lab is the foundation of that.”

Zach Brennan @ZacharyBrennan

Scoop: Trump admin reverses course on FDA drug quality lab lease termination - https://t.co/7Iq03jgYXx

AbbVie enters the obesity drug field via a deal for Gubra’s Phase 1 amylin analog at $350M upfront (~10x Gubra’s ‘24 revenue) I spoke with Henrik Blou, CEO of the Chicago drug giant’s new Danish biotech partner, this morning for @endpts https://t.co/OZvDDdvu6q